Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: GONORRHEA: A BRIEF INTRODUCTION • What is gonorrhea? • What causes gonorrhea? • What are the various symptoms of gonorrhea? • How is gonorrhea treated? PART 06: MARKET LANDSCAPE • Market overview • Market size and forecast • Five forces analysis PART 07: PIPELINE PART 08: MARKET SEGMENTATION BY APPLICATION • Monotherapy • Market size and forecast • Dual therapy • Market size and forecast PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast • EMEA – Market size and forecast • APAC – Market size and forecast • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Rising government initiatives to combat antibiotic resistance • Advent of vaccine for prevention of gonorrhea • Expedited Partner Therapy (EPT) PART 13: VENDOR LANDSCAPE • Competitive landscape PART 14: KEY VENDOR ANALYSIS • Bharat Pharmaceuticals • GlaxoSmithKline • Merck • Pfizer • Other prominent vendors PART 15: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Incidence rate of gonorrhea in US, 2008 (per 100,000 population) Exhibit 02: Symptoms of gonorrhea Exhibit 03: Global gonorrhea therapeutics market: Snapshot Exhibit 04: Global gonorrhea therapeutics market, 2016-2021 ($ millions) Exhibit 05: Opportunity analysis of global gonorrhea therapeutics market Exhibit 06: Five forces analysis Exhibit 07: Key clinical trials Exhibit 08: Global gonorrhea therapeutics market: Segmentation by application Exhibit 09: Global gonorrhea therapeutics market share by application, 2016 Exhibit 10: Global gonorrhea monotherapy therapeutics market, 2016-2021 ($ millions) Exhibit 11: Global gonorrhea dual therapy therapeutics market, 2016-2021 ($ millions) Exhibit 12: Global gonorrhea therapeutics market share by region, 2016 and 2021 Exhibit 13: Global gonorrhea therapeutics market revenue by region, 2016-2021 ($ millions) Exhibit 14: Global gonorrhea therapeutics market share by region, 2016-2021 Exhibit 15: Regional comparison Exhibit 16: Gonorrhea therapeutics market in Americas 2016-2021 ($ millions) Exhibit 17: Gonorrhea therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 18: Gonorrhea therapeutics market in APAC 2016-2021 ($ millions) Exhibit 19: Key leading countries Exhibit 20: Travel associated gonorrhea cases by region, 2008-2013 Exhibit 21: Prevalence rate of gonorrhea, 2009 Exhibit 22: Prevalence rate of gonorrhea by age and race Exhibit 23: Infertility ratio in males and females Exhibit 24: Revenue history for Zithromax/Zmax, 2005-2016 Exhibit 25: Pictorial presentation of EPT Exhibit 26: Competitive structure analysis of global antibiotics market 2016 Exhibit 27: Bharat Pharmaceuticals: Strength assessment Exhibit 28: Bharat Pharmaceuticals: Strategy assessment Exhibit 29: Bharat Pharmaceuticals: Opportunity assessment Exhibit 30: GlaxoSmithKline: Key highlights Exhibit 31: GlaxoSmithKline: Strength assessment Exhibit 32: GlaxoSmithKline: Strategy assessment Exhibit 33: GlaxoSmithKline: Opportunity assessment Exhibit 34: Merck: Key highlights Exhibit 35: Merck: Strength assessment Exhibit 36: Merck: Strategy assessment Exhibit 37: Merck: Opportunity assessment Exhibit 38: Pfizer: Key highlights Exhibit 39: Pfizer: Strength assessment Exhibit 40: Pfizer: Strategy assessment Exhibit 41: Pfizer: Opportunity assessment

Bharat Pharmaceuticals, GlaxoSmithKline, Merck, Pfizer, Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.